Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | You, Dong-Joo | - |
dc.contributor.author | Park, Cho Rong | - |
dc.contributor.author | Furlong, Michael | - |
dc.contributor.author | Koo, Okjae | - |
dc.contributor.author | Lee, Cheolju | - |
dc.contributor.author | Alm, Curie | - |
dc.contributor.author | Seong, Jae Young | - |
dc.contributor.author | Hwang, Jong-Ik | - |
dc.date.accessioned | 2024-01-20T05:34:16Z | - |
dc.date.available | 2024-01-20T05:34:16Z | - |
dc.date.created | 2021-09-05 | - |
dc.date.issued | 2015-11 | - |
dc.identifier.issn | 0898-6568 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/124796 | - |
dc.description.abstract | I kappa B kinases (IKKs) are a therapeutic target due to their crucial roles in various biological processes, including the immune response, the stress response, and tumor development. IKKs integrate various upstream signals that activate NF-kappa B by phosphorylating I kappa B and also regulate many proteins related to cell growth and metabolism. Although they function as a heteromeric complex comprised of kinase subunits and an adaptor, these kinases produce distinct cellular responses by phosphorylating different target molecules, suggesting that they may also be regulated in a subtype-specific manner. In this study, arfaptin 2 was identified as an IKK beta-specific binding partner. Interestingly, arfaptin 2 also interacted with NEMO. Domain mapping studies revealed that the C-terminal region, including the IKK beta HLH domain and the first coiled-coil NEMO region were respectively required for interactions with the arfaptin 2 N-terminal flexible region. Overexpression of arfaptin 2 inhibited tumor necrosis factor (TNF)-alpha-stimulated nuclear factor-kappa B (NF-kappa B) signaling, whereas downregulation of arfaptin 2 by small interfering RNA enhanced NF-kappa B activity. Dimerization of arfaptin 2 through the Bin-Amphiphysin-Rvs domain may be essential to inhibit activation of NF-kappa B through multimodal interactions with IKK beta s or IKK beta/NEMO, as ectopic expression of the arfaptin 2 fragment responsible for IKK interactions did not change TNF alpha-stimulated NF-kappa B activation. These data indicate that arfaptin 2 is the first molecule to regulate NF-kappa B signaling by interacting with the functional IKK complex but not by direct inhibiting IKK beta phosphorylation. (C) 2015 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.subject | RAC1-INTERACTING PROTEIN | - |
dc.subject | ACTIVATION | - |
dc.subject | PHOSPHORYLATION | - |
dc.subject | COMPLEX | - |
dc.subject | NEMO | - |
dc.subject | TRANSCRIPTION | - |
dc.subject | BINDING | - |
dc.subject | TUMORIGENESIS | - |
dc.subject | PATHWAYS | - |
dc.subject | CANCER | - |
dc.title | Dimer of arfaptin 2 regulates NF-kappa B signaling by interacting with IKK beta/NEMO and inhibiting IKK beta kinase activity | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.cellsig.2015.08.012 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | CELLULAR SIGNALLING, v.27, no.11, pp.2173 - 2181 | - |
dc.citation.title | CELLULAR SIGNALLING | - |
dc.citation.volume | 27 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 2173 | - |
dc.citation.endPage | 2181 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000361777500004 | - |
dc.identifier.scopusid | 2-s2.0-84941260687 | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | RAC1-INTERACTING PROTEIN | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | PHOSPHORYLATION | - |
dc.subject.keywordPlus | COMPLEX | - |
dc.subject.keywordPlus | NEMO | - |
dc.subject.keywordPlus | TRANSCRIPTION | - |
dc.subject.keywordPlus | BINDING | - |
dc.subject.keywordPlus | TUMORIGENESIS | - |
dc.subject.keywordPlus | PATHWAYS | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | I kappa B kinases | - |
dc.subject.keywordAuthor | Arfaptin 2 | - |
dc.subject.keywordAuthor | NF-kappa B | - |
dc.subject.keywordAuthor | TNF-alpha | - |
dc.subject.keywordAuthor | BAR domain | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.